Immunooncology Collaborations on the Rise

While Incyte and Genentech announced partnership to study each of their immunooncology molecules in NSCLC, AstraZeneca and Kyowa Hakko Kirin signed a similar agreement to evaluate their candidate molecules in multiple solid tumors.

Incyte Corporation (INCY) announced today that it has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech’s PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell lung cancer (NSCLC).

Both INCB24360 and MPDL3280A are part of a new class of cancer treatments known as immunotherapies that are designed to enhance the body’s own defenses in fighting cancer; both agents target distinct regulatory components of the immune system.

Source: Yahoo!finance

AstraZeneca today announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.

The study will evaluate AstraZeneca’s anti-PD-L1 antibody, MEDI4736, in combination with Kyowa Hakko Kirin’s anti-CCR4 antibody, mogamulizumab, and AstraZeneca’s anti-CTLA-4 antibody tremelimumab, in combination with mogamulizumab.

Source: PipelineReview

Related Videos
Related Content
© 2023 MJH Life Sciences
All rights reserved.